[1]王 磊,赵 颖,刘红星.三种质谱仪测定血液环孢素A 浓度性能确证和优选研究[J].现代检验医学杂志,2020,35(04):118-123.[doi:10.3969/j.issn.1671-7414.2020.04.030]
　WANG Lei,ZHAO Ying,LIU Hong-xing.Performance Validation and Optimization Studies of the Determination of Cyclosporine A Concentration in Blood by Three Mass Spectrometers[J].Journal of Modern Laboratory Medicine,2020,35(04):118-123.[doi:10.3969/j.issn.1671-7414.2020.04.030]
点击复制

三种质谱仪测定血液环孢素A 浓度性能确证和优选研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年04期
页码:
118-123
栏目:
研究简报 实验技术
出版日期:
2020-09-05

文章信息/Info

Title:
Performance Validation and Optimization Studies of the Determination of Cyclosporine A Concentration in Blood by Three Mass Spectrometers
文章编号:
1671-7414（2020）04-118-06
作者:
王 磊1;  赵 颖1;  刘红星1; 2
（1. 河北燕达陆道培医院, 河北三河 065201；2. 北京陆道培血液病研究院，北京 100176）
Author(s):
WANG Lei1;  ZHAO Ying1;  LIU Hong-xing1; 2
(1. Hebei Yanda Lu Daopei Hos pital ,Hebei Sanhe 065201, China;2. Beijing Lu Daopei I nstitute of Hematology, Beijing 100176, China)
关键词:
环孢素A; 高效液相色谱串联质谱法; 性能确证
分类号:
R969；Q503
DOI:
10.3969/j.issn.1671-7414.2020.04.030
文献标志码:
A
摘要:
目的 比较环孢素A（CsA）血药浓度测定在TRIPLE QUADTM 4500 MD,4000 Q TRAP 和API 3200 MD 三台质谱仪上的性能确证结果，优选出一台更适合环孢素A 血药浓度测定的质谱仪。方法 对三台质谱仪上环孢素A 血药浓度测定的方法学、定量下限、精密度、准确度、残留、基质效应和稳定性进行比较，并对同一批临床样本在三台质谱仪上的检测结果进行分析。结果 环孢素A 在TRIPLE QUADTM 4500 MD,4000 Q TRAP 和API 3200 MD 上的检测时间分别为3.0，3.0 和4.0min，峰型均良好；最低定量限分别为1.7, 0.7 和2.1 ng/ml；批内及批间标准偏差均小于5%，回收率均大于90%，残留均小于5%，内标归一化基质因子分别为94.96% ~ 106.02%，88.96% ~ 95.47% 和99.14%~ 107.82%；24h 的CV 在TRIPLE QUADTM 4500 MD 和4000 Q TRAP 上均小于10%，在API 3200 MD 上CV 小于5%。同一批临床样本在三台质谱仪上的检测结果差异无统计学意义（P=0.665）。结论 环孢素A 血药浓度测定在三台质谱仪上均可进行，但从合规性和检测通量上宜选用TRIPLE QUADTM 4500 MD。

参考文献/References:

[1] 环孢素软胶囊中文说明书[Z].2010 年版. 丽珠集团丽珠制药厂. Chinese Instructions for cyclosporine Soft Cpsules[Z].2010 Edition. Lizhu Pharmaceutical Factory of LizhuGroup.
[2] JOHNSTON A, HOLT D W. Immunosuppressantdrugs-the role of therapeutic drug monitoring[J]. Br JClin Pharmacol, 2001,52(Suppl 1):61S-73S.
[3] JORGA A, HOLT D W, JOHNSTON A. Therapeuticdrug monitoring of cyclosporine[J]. Transplant Proc,2004,36(2suppl):396S-403S.
[4] ZHANG Yu, ZHANG Rui. Recent advances inanalytical methods for the therapeutic drug monitoringof immunosuppressive drugs[J]. Drug Test Anal,2017,10(1):81-94.
[5] KAHAN B D, KEOWN P, LEVY G A, et al.Therapeutic drug monitoring of immunosuppressantdrugs in clinical practice[J].Clin Ther,2002,24(3):330-350.
[6] 中华医学会儿科学分会临床药理学组. 儿童治疗性药物监测专家共识[J]. 中华儿科杂志,2015,53(9):650-659. Clinical Pharmacology Group, Pediatrics Society ofthe Chinese Medical Association. Expert consensus ontherapeutic drug monitoring in children [J]. ChineseJournal of Pediatrics, 2015,53(9):650-659.
[7] 国家卫生计划生育委员会临床检验中心. 卫生部临床检验中心室间质量评价标准[S]. 北京: 中国标准出版社，2017. General Administration of Quality SupervisionInspection and Quarancine of the People’s Repablicof China. Inter-laboratory quality evaluation standardof clinical testing center of the ministry of health [S].Beijing :Standard Press of China, 2017.
[8] 王磊, 孙文利, 陈佳琦, 等. 环孢素A 血药浓度监测相关实验室检测研究进展[J]. 中华临床实验室管理电子杂志,2019,7(02):65-70. WANG Lei, SUN Wenli, CHEN Jiaqi,et al. Researchprogress on laboratory monitoring cyclosporineA concentration in the whole blood[J]. ChineseJournal of Clinical Laboratory Mgt (ElectronicEdition),2019,7(2):65-70.
[9] 蒋志美, 张伶俐, 罗婷, 等. 高效液相色谱法与常见免疫法监测环孢素血药浓度效果比较的系统评价[J]. 中国医院用药评价与分析,2018,18(3):289-294. JIANG Zhimei, ZHANG Lingli, LUO Ting,et al.Systematic reviewon comparison of effects betweenperformance liquid chromatography and commonimmunoassay in monitoring the plasma concentrationof cyclosporin A [J]. Evaluation and Analysis of DrugUse in Hospitals of China, 2008,18(3):289-294.
[10] 王磊, 刘红星, 孙文利.HPLC-MS/MS 法在骨髓移植患者全血 CSA 及 AM1 浓度 测 定 中的应用[J]. 重庆医学,2017,46 (23):3234-3237. WANG Lei, LIU Hongxing, SUN Wenli. TheApplication of HPLC-MS/MS method in thedetermination of whole blood concentration ofcyclosporine A and AMI in bone marrow transplantpatient [J]. Chong qing Med,2017, 46 (23): 3234-3237.
[11] DAVID W H, MSTRONG V W, GRIESMACHER A,et al. International federation of clinical chemistry/international association of therapeutic drugmonitoring and clinical toxicology working group onimmunosuppressive drug monitoring[J].TherapeuticDrug Monitoring,2002,24(1):59-67.
[12] MORRIS R G,ILETT KENNETH F,TETT SUSANE,et al. Cyclosporin monitoring in Australasia: 2002update of consensus guidelines[J]. Therapeutic drugmonitoring,2002,24(6):677-688.
[13] WHO.WHO model formulary for children 2010[EB/OL].
[2018-10-28]. http://apps.who.int/medicinedocs/en/m/abstract/Js17151e/.
[14] https://www.mayoclinic.org/search/search-results?q=Cyclosporine.2020.1.15.
[15] 中国药理学会治疗药物监测研究专业委员会. 治疗药物监测工作规范专家共识(2019 版)[J]. 中国医院用药评价与分析,2019,19(8):897-902. Division of Therapeutic Drug Monitoring, ChinesePharmacological Society. The expert consensus on thestandards of therapeutic drug monitoring(2019 Edition)[J]. Evaluation and Anolysis of Drug-Use in Hospitalsof China, 2019,19(8):897-902.
[16] 国家药典委员会. 中华人民共和国药典[M]. 北京:中国医药科技出版社,2015:363. Chinese Pharmacopoeia committee. Pharmacopoeiaof the People’s Republic of China [M]. Beijing: ChinaMedical Science and Technology Press,2015:363.
[17] Clinical and Laboratory Standards Institute. LiquidChromatography-mass spectrometry methods approvedguideline[S]. Wayne PA: CLSI C62-A, 2014.
[18] 中华医学会检验医学分会，国家卫生计划生育委员会临床检验中心. 液相色谱- 质谱临床应用建议[J].中华检验医学杂志, 2017,40(10):770-779. Chinese Society of Laboratory Medicine, NationalCenter for Clinical Laboratories. Suggestions onclinical application of liquid chromatography-massspectrometry [J]. Chinese Journal of LaboratoryMedicine, 2017,40(10):770-779.
[19] BURLINGAME A L, BOYD R K, GASKELL S L.Mass spectrometry[J]. Anal Chem,1994,66(12):634R-683R.
[20] European Medicines Agency. Guideline on validationof bioanalytical methods[S]. United Kingdom: London,2009.

相似文献/References:

[1]李 敏,孙江漫,孟祥兆,等.北京地区老年人群血浆维生素A，D 和E 水平检测结果分析[J].现代检验医学杂志,2022,37(05):159.[doi:10.3969/j.issn.1671-7414.2022.05.031]
　LI Min,SUN Jiang-man,MENG Xiang-zhao,et al.Analysis of Plasma Vitamin A，D and E Levels in Beijing Elderly Population[J].Journal of Modern Laboratory Medicine,2022,37(04):159.[doi:10.3969/j.issn.1671-7414.2022.05.031]

备注/Memo

备注/Memo:
收稿日期：2020-02-13修回日期：2020-03-24作者简介：王磊（1984-），男，硕士，助理研究员，主要从事医院药学研究工作，E-mail：rosie1982@163.com。通讯作者：刘红星，男，医学硕士，副研究员，主要从事血液病相关实验室研究。
更新日期/Last Update: 2020-10-08